Contineum Therapeutics (CTNM) Enterprise Value (2023 - 2026)

Contineum Therapeutics' Enterprise Value history runs 4 years deep, the most recent figure standing at -$246.3 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 29.16% year-over-year to -$246.3 million; the TTM figure through Mar 2026 stood at -$246.3 million (down 29.16% YoY), while the FY2025 annual figure was -$262.9 million, down 28.39% from the prior year.
• Enterprise Value was -$246.3 million for Q1 2026 at Contineum Therapeutics, up from -$262.9 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$117.9 million in Q1 2024 to a low of -$262.9 million in Q4 2025.
• Historically, Enterprise Value has averaged -$193.8 million across 4 years, with a median of -$197.7 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Enterprise Value slumped 63.56% in 2024, then increased 19.74% in 2025.
• A 4-year view of Enterprise Value shows it stood at -$125.2 million in 2023, then plunged by 63.56% to -$204.8 million in 2024, then slipped by 28.39% to -$262.9 million in 2025, then rose by 6.3% to -$246.3 million in 2026.
• The last three Enterprise Value figures came in at -$246.3 million (Q1 2026), -$262.9 million (Q4 2025), and -$182.4 million (Q3 2025), per Business Quant data.